Normalised net profit before tax $507m, down 8%Normalised net...

Normalised net profit before tax $507m, down 8%
Normalised net profit after tax $344m, down 13%
Statutory net loss after tax $416m
Normalised EPS2 56.5 cents per share, down 14%
Statutory EPS2 negative 68.4 cents per share
Net income $797m, down 3%
Expenses $284m, up 6%
Normalised cost to income ratio 35.7%, up 310bps
Group assets under management $85.2bn, up 4%
Normalised Return On Equity (pre-tax) 14.8%, down 180bps
Full-year dividend 17.5 cents per share (fully franked), down 18.0 cents per share
Normalised dividend payout ratio 31.0%
Life Cash Operating Earnings (COE) $639m, down 5%
COE margin 3.32%, down 30bps
Expenses $114m, up 7% driven by investment in DPM growth initiatives3
Normalised EBIT4 $525m, down 7%
Total Life sales $5.2bn, up 13%
Total Life book growth $316m, or 2.1% of opening liabilities
Annuity sales $3.1bn, down 12%, with domestic sales down 27% and Japan sales up 177%
Annuity net book growth -$251m, or -2.0% of opening liabilities
Average investment assets $19.2bn, up 4%
Normalised Return On Equity (pre-tax) 16.6%, down 120bps
Prescribed Capital Amount (PCA) ratio 1.81 times, up from 1.53 times at FY19
Common Equity Tier 1 (CET1) ratio 1.20 times, up from 1.06 times at FY19
Capital intensity 10.7%, down from 13.8% at FY19
Funds Management Net income $158m, up 5%
Expenses $100m, up 1%
EBIT $58m, up 13%
Net flows $2.5bn
Funds Under Management (FUM) $81.4bn, up 3%
Return On Equity (pre-tax) 24.3%, up from 23.5% in FY19